Tandem Diabetes Care Posts Record Sales but Faces Pay-As-You-Go Transition Challenges
Event summary
- Tandem Diabetes Care reported $290.4 million in Q4 2025 sales, a 3% increase from the prior year.
- Full-year 2025 revenue hit $1.015 billion, with international sales growing 15%.
- The company launched global commercial rollout of t:slim X2 pump integration with FreeStyle Libre 3 Plus sensor.
- Tandem introduced a pay-as-you-go pharmacy structure in the U.S., expected to create a $70–80 million headwind in 2026.
- 2026 guidance projects $1.065–1.085 billion in sales, with gross margin estimated at 56–57%.
The big picture
Tandem Diabetes Care is navigating a strategic shift toward more predictable revenue streams with its pay-as-you-go model, while expanding its global footprint. The company’s record sales and operational improvements in 2025 highlight its growing market presence, but the transition to new business models poses execution risks. Success will depend on balancing short-term financial impacts with long-term growth potential.
What we're watching
- Revenue Impact
- How the pay-as-you-go model transition will affect Tandem's near-term revenue growth.
- International Expansion
- Whether direct commercial operations in select European countries can drive sustained international sales growth.
- Regulatory Progress
- The pace at which the FDA approval for Control-IQ+ technology's pregnancy indication will advance market opportunities.
Related topics